KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Minority Interest (2020 - 2026)

AbbVie has reported Minority Interest over the past 6 years, most recently at $42.0 million for Q4 2025.

  • Quarterly Minority Interest rose 7.69% to $42.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.0 million through Dec 2025, up 7.69% year-over-year, with the annual reading at $42.0 million for FY2025, 7.69% up from the prior year.
  • Minority Interest was $42.0 million for Q4 2025 at AbbVie, down from $43.0 million in the prior quarter.
  • Over five years, Minority Interest peaked at $45.0 million in Q2 2025 and troughed at $23.0 million in Q1 2021.
  • The 5-year median for Minority Interest is $35.0 million (2022), against an average of $35.0 million.
  • Year-over-year, Minority Interest soared 42.11% in 2021 and then fell 8.57% in 2023.
  • A 5-year view of Minority Interest shows it stood at $28.0 million in 2021, then increased by 17.86% to $33.0 million in 2022, then rose by 12.12% to $37.0 million in 2023, then increased by 5.41% to $39.0 million in 2024, then increased by 7.69% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Minority Interest are $42.0 million (Q4 2025), $43.0 million (Q3 2025), and $45.0 million (Q2 2025).